JASPER THERAPEUTICS, INC.

Analyst Reco. Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
20.92 ^USD	+0.77%		-8.12%	+165.15%

05-13	Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	MT
05-07	Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	05-06	MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	04-03	MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	03-28	MT
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	03-18	MT
Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target	11/08/23	MT
EF Hutton Assumes Jasper Therapeutics at Buy With $6.85 Price Target	25/05/23	MT
EF Hutton Raises Price Target on Jasper Therapeutics to $6.85 From $4, Maintains Buy Rating	16/02/23	MT
Credit Suisse Lowers Jasper Therapeutics' PT to $3 From $7 After Announcing Pipeline Reprioritization, Keeps Outperform Rating	11/01/23	MT
Oppenheimer Adjusts Jasper Therapeutics Price Target to $8 From $21, Maintains Outperform Rating	14/11/22	MT
EF Hutton Starts Jasper Therapeutics at Buy With $4 Price Target	01/11/22	MT
Credit Suisse Lowers Jasper Therapeutics' Price Target to $8 from $9 on Moderately Tempered Peak Market Share Assumption, Keeps Outperform Rating	13/07/22	MT
Cantor Fitzgerald Starts Jasper Therapeutics at Overweight With $10 Price Target	28/02/22	MT
Credit Suisse Trims Jasper Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating	25/02/22	MT
Credit Suisse Starts Jasper Therapeutics at Outperform with $15 Price Target	08/11/21	MT
JASPER THERAPEUTICS : William Blair Initiates Jasper Therapeutics at Outperform Rating	21/10/21	MT
JASPER THERAPEUTICS : BMO Initiates Jasper Therapeutics at Outperform Rating With $19 Price Target	20/10/21	MT
Jasper Therapeutics : Shares Soar Midday After Initiated by Oppenheimer With Outperform Rating, $21 Price Target	13/10/21	MT
JASPER THERAPEUTICS : Oppenheimer Starts Jasper Therapeutics at Outperform with $21 Price Target	13/10/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer